{"id":5102,"name":"Pathway Bioventures","slug":"pathway-bioventures","website":"https://www.pathwaybioventures.com","hqGeo":"Cambridge, MA","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Healthcare","Other"],"excludedSectors":["Consumer","Media"],"checkSizeMin":250000,"checkSizeMax":3000000,"thesisSummary":"Dedicated to early-stage biotech with cutting-edge innovations in oncology and cell therapy solutions, focusing on niche applications.","thesisNarrative":null,"logoUrl":null,"aumUsd":null,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"BioRegen Therapeutics","companyUrl":null,"stage":null,"sector":"Cell & Gene Therapy","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"TumorTarget Biotech","companyUrl":null,"stage":null,"sector":"Oncology","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"AIRNA Therapeutics","companyUrl":null,"stage":"Preclinical development","sector":"RNA Editing","investmentYear":null,"description":"Pioneering the discovery and development of RNA editing therapeutics for patients with rare and common diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"AXONIS Therapeutics","companyUrl":null,"stage":"Preclinical development","sector":"Small Molecule","investmentYear":null,"description":"Advancing breakthroughs in neuroscience to develop first-in-class precision therapies for neurological disorders.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"BioGraph55","companyUrl":null,"stage":"Preclinical development","sector":"Bispecific Antibody","investmentYear":null,"description":"Developing bispecific antibodies against a novel subset of immunosuppressive cells to treat resistant cancers.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"IpiNovyx Bio","companyUrl":null,"stage":"Preclinical development","sector":"Small molecule","investmentYear":null,"description":"Develops next-generation, ultra-selective proteasome inhibitors for oncology and autoimmune disease applications.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"miRecule","companyUrl":null,"stage":"Preclinical development","sector":"Antibody-RNA Conjugate","investmentYear":null,"description":"Developing RNA-based therapeutics for cancer and muscular dystrophy.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Modifi Bio","companyUrl":null,"stage":"Preclinical-stage","sector":"Small molecule","investmentYear":null,"description":"Creating a new class of oral medicines that selectively kill cancer cells via direct DNA modification.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Nionyx Bio","companyUrl":null,"stage":"Preclinical development","sector":"Gene therapy","investmentYear":null,"description":"Developing transformative gene therapies for patients with severe kidney diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Ochre Bio","companyUrl":null,"stage":"Preclinical development","sector":"sirna","investmentYear":null,"description":"Developing novel RNA-based therapeutics for chronic liver diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Scioto Biosciences","companyUrl":null,"stage":"Clinical-stage","sector":"Live bacterial therapeutic","investmentYear":null,"description":"Developing bacterial therapeutics for GI and neurological diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"4BIO","companyUrl":null,"stage":null,"sector":"venture fund","investmentYear":null,"description":"A leading specialist investor in advanced modalities including cell, gene, RNA, and targeted therapies.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Afference","companyUrl":null,"stage":null,"sector":"bioelectronics","investmentYear":null,"description":"Leveraging advances in neural engineering to create an artificial sense of touch.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Cytovale","companyUrl":null,"stage":null,"sector":"diagnostic","investmentYear":null,"description":"Interrogates biomechanical properties of immune cells to rapidly diagnose sepsis and other severe immunological diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Dimension Inx","companyUrl":null,"stage":null,"sector":"Medical device","investmentYear":null,"description":"Creates advanced biomaterials and biofunctional 3D-printed implants for tissue regeneration and repair.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Simergent","companyUrl":null,"stage":null,"sector":"medical device","investmentYear":null,"description":"Building an automated peritoneal dialysis device that can provide cheaper, safer, and smarter home-based dialysis.","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":5,"partners":[{"id":14955,"name":"Daniel Jacobs","title":"Managing Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/danielijacobs","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14959,"name":"Jacob Segil, PhD","title":"Venture Partner","seniority":null,"focusTags":["medical devices","neural interfaces","prosthetic devices","translation into devices"],"linkedinUrl":"https://www.linkedin.com/in/jacobsegil","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14958,"name":"Matt Martin, PhD, MBA","title":"Partner","seniority":null,"focusTags":["therapeutics","unmet medical needs","life sciences startups","investment strategy"],"linkedinUrl":"https://www.linkedin.com/in/matt-martin-pathwaybioventures","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14957,"name":"Daniel Jacobs, PhD, MPH","title":"Founder & Managing Partner","seniority":null,"focusTags":["cancer epidemiology","genomics","RNA therapeutics","precision therapeutics","early-stage life sciences"],"linkedinUrl":"https://www.linkedin.com/in/danieljacobs-bioventures","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14956,"name":"Emily Nguyen","title":"Founding GP","seniority":null,"focusTags":["Biotech","Cell Therapy","HealthTech"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsLast12Months":0},"investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":12955,"name":"Jovono","slug":"jovono","logoUrl":null,"website":"https://jovono.com","stageFocus":["Seed","Series A"],"sectorTags":["Other","Climate / Energy","Fintech","Consumer","SaaS","Healthcare"],"hqGeo":"Los Angeles, CA"},{"id":13015,"name":"Nile Ventures","slug":"nile-ventures-13015","logoUrl":null,"website":"https://www.choosenile.com/","stageFocus":["Pre-Seed"],"sectorTags":["Healthcare","SaaS"],"hqGeo":"Lagos, Nigeria"},{"id":9065,"name":"Sdv","slug":"sdv","logoUrl":null,"website":"https://sdv.vc","stageFocus":["Pre-Seed","Seed"],"sectorTags":["SaaS","Fintech","Healthcare","AI / ML"],"hqGeo":null},{"id":13026,"name":"Robin Capital","slug":"robin-capital","logoUrl":null,"website":"https://robincap.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["AI / ML","Fintech","SaaS","Other","Climate / Energy","Healthcare"],"hqGeo":"Berlin, Germany"},{"id":10202,"name":"Celestial Health Innovators","slug":"celestial-health-innovators","logoUrl":null,"website":"https://celestialhealthwellness.co/","stageFocus":["seed+","Series A"],"sectorTags":["Healthcare","Other"],"hqGeo":"New York, NY"},{"id":12096,"name":"TeleHealth Ventures","slug":"telehealth-ventures","logoUrl":null,"website":"https://telehealthventures.com","stageFocus":["Seed"],"sectorTags":["Other","Healthcare"],"hqGeo":"Austin, TX"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"how-many-investors-should-you-pitch","title":"How Many Investors Should You Pitch? The Math Most Founders Get Wrong"},{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"},{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-06-14T19:03:49.323Z"}